Non-prescription drugs to be sold at neighbourhood grocery stores soon: Report
In a move that aims to make non-prescription drugs more accessible for people, the Drugs Technical Advisory Board (DTAB) decided in April that such drugs can be sold at grocery stores, the Mint report said citing three people familiar with the matter. However, no official notification has been issued yet.
There are several drugs that can be bought in India without a signed prescription from a doctor, such as painkillers, cough syrups, anti-allergics, laxatives and anti-fungal products. These are also called over-the-counter (OTC) drugs. While the retail store owners won't need to hire a pharmacist for the sale of these drugs, they will have to obtain a licence, said the report.
According to one of three sources, the government has been working on making this happen for quite some time now and a final decision is not far away. 'The government is finalizing the list of OTC drugs and products which can be sold at retail shops. The government has been working on this for a long time, and a final decision is to be taken shortly," the report quoted the person as saying, who also attended the DTAB meeting.
The second official familiar with the matter told Mint that the government is working on formulating new regulations that will define what these OTC drugs are. 'Right now, OTC drugs are not defined or covered under the Drugs Rule, 1945. Once these regulations are in place, the public will be aware of what OTC drugs are, and what types of drugs can be purchased without a prescription…The move is aimed at ensuring accessibility and availability of OTC drugs to the people even in the interiors of the villages and remote areas," the official said.
While the move may prove beneficial for people for cutting down their trip to a medical store to get a non-prescription drug, it puts medical stores and chemists at a risk of loss of sales. The All India Organization of Chemists and Druggists (AIOCD) is not in favour of the move and has been opposing it.
Expressing concern over how the move will unfold and affect chemists, AIOCD's general secretary Rajiv Singhal said, 'Where will we go? This will put the growth of pharmacists at risk.' He said that letting retail stores sell OTC drugs can lead to misuse and had urged the government to consult and be transparent with chemists before making any decision.
"We are going to submit our representation to the government to seek a transparent and balanced approach in finalizing the sale of OTC drugs at retail level and involve stakeholders like the Indian Medical Association, doctors and Indian Pharmaceutical Association (IPA) before finalizing the change," he said.
According to the third person familiar with the matter, a list of OTC drugs has already been prepared by the sub-committee and is on the way of getting a final nod after the government re-issues a 'draft notification on OTC drugs regulation' and takes stakeholders' comments.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
3 days ago
- Mint
Inside Cipla's battle with ‘superbugs' as antibiotic resistance rises in India
Mumbai-headquartered drugmaker Cipla Ltd is bolstering its focus on a pipeline of drugs to fight infections caused by bacterial antimicrobial resistance in India, a growing health crisis. The company, a leader in the infectious diseases segment, has already launched two antibiotics targetting such superbugs, and sees the segment as a long-term focus area, a senior executive told Mint. 'Since we began our work on (antimicrobial drug resistance), our strategic plan has been to introduce three to four products in the AMR space over a 5-year horizon," Dr. Jaideep Gogtay, Cipla's global chief medical officer, said in an interview. 'I think it will be a long-term strategy. As a company which remains focused on India, there is no option for us to not be in the antibiotics segment," Gogtay added. Antimicrobial drug resistance occurs when microorganisms like bacteria or fungi evolve to resist the drugs designed to kill or inhibit them. These 'superbugs' render existing treatments ineffective and can lead to escalation of the infection, and cause death as well. Bacterial antimicrobial resistance was associated with 4.71 million global deaths in 2021, according to a Lancet study. This could increase to 39 million by 2050. India, which is one of the world's largest antibiotic markets, also has one of the highest burdens of drug resistance. Overuse of antibiotics is leading to increasing resistance in the community, while new drug development has not kept pace with the growing threat. 'Out of every 100 new drugs developed, only one or two are antibiotics. Although we know, in the future antibiotic-resistant infections are going to probably kill more people than cancer infections," Gogtay said. Globally, the development focus has shifted away from infectives and antibiotics to therapies like cancer and obesity, with most large pharma companies exiting antibiotic research. Cipla's pipeline Cipla has launched two drugs targeted at bacterial AMR in the past year. In May, it became the first company to launch plazomicin, marketed under brand name Zemdri, in India, a novel anti-microbial with demonstrated activity against multi-drug resistant bacteria and clinical efficacy in complicated urinary tract infections (cUTI). Clinical efficacy refers to how well a drug or treatment method achieves its intended effect under controlled clinical trials. Last year, Cipla partnered with Chennai-based Orchid Pharma Ltd to launch its novel antibiotic Cefepime-Enmetazobactam, which has been approved for the treatment of cUTIs, hospital-acquired pneumonia, and ventilator-associated pneumonia. The company plans to launch this year a non-antibiotic that can be used to prevent cUTIs without the risk of developing resistance. 'We are working with a partner, and the product has been approved in India. We will launch this product in India shortly," said Gogtay. For 2024-25, Cipla reported a revenue of ₹27,548 crore, up 8% year-on-year, while profit after tax surged 28% to ₹5,273 crore. How big is the market? The overall market for anti-infective drugs in India was ₹26,824 crore in May in terms of moving annual total (MAT) sales, according to pharma intelligence platform Pharmarack. Of this, antibiotics accounted for sales worth ₹23,127 crore. (MAT sales refers to total sales over the past 12 months, calculated on a rolling basis.) However, it is hard to zero in on the size of the market for drugs specifically targeted at drug-resistant bacteria, according to experts. Drugs that target antimicrobial drug resistance are given after the first or second line of antibiotics prove to be ineffective in treating a patient. However, as resistance increases, the market is growing. 'Here, what they (Cipla) seem to be trying to do is identify certain areas which may be meaningful over a period of time and try to get in early. They are trying to be early in an area that may become a lot more relevant in the future," said Prashant Nair, analyst for healthcare and pharma at Ambit Capital. Anti-infective medicines make for a key therapy segment for Cipla, after respiratory, cardiac and urology, said Nair. 'Most players who are strong in anti-infectives therapy may be looking at this space." Apart from Cipla, Wockhardt Ltd too has been sharpening its focus on antimicrobial drug resistance, with a pipeline of six novel antibiotics, of which two have been launched in India. As on 3 July, Cipla shares were down by about 1.4% each since the beginning of the year, while Wockhardt shares were up nearly 20% on NSE. The Nifty Pharma index was down more than 5% year-to-date.
&w=3840&q=100)
Business Standard
4 days ago
- Business Standard
Is your makeup safe? Govt may soon ban mercury-based cosmetics in India
The Government of India is considering a ban on mercury-based cosmetics following a recommendation from a Drugs Controller General of India (DCGI) subcommittee, Mint reported, citing official documents. The move aims to identify and phase out mercury-containing products from India's ₹20-billion cosmetics market, including online platforms, and align with international safety standards. Mercury in cosmetics: Why you should be concerned Ever wondered what's really inside your favourite cosmetic products? You might want to take a closer look at the label—because the toxic metal mercury could be hiding in your eyeliner or skin cream. Mercury isn't just harmful to the skin; it's a health hazard that can seep into your bloodstream and cause long-term damage. It can cause skin rashes, discolouration, thinning of the skin, and even permanent scarring. According to the Mint report, mercury-based products such as skin-lightening creams, anti-ageing solutions, and some eye makeup items are particularly risky. These often deliver quick, 'miracle' results that tempt consumers—especially the young—but the long-term effects can be deeply damaging. What do the current rules say about mercury in makeup? Currently, Indian regulations permit limited mercury use. According to Rule 39(5) of the Cosmetics Rules, 2020, cosmetics meant for the eye area may contain up to 70 parts per million (0.007 per cent) of mercury as a preservative. For all other cosmetics, mercury should not exceed 1 ppm. However, the DCGI's subcommittee is advocating a stricter standard—a complete ban on the manufacture, import, and export of any cosmetic containing more than 1 ppm of mercury. This would bring India in line with the Minamata Convention, which seeks to eliminate mercury from consumer products globally. Self-declaration, surprise tests planned for compliance Cosmetic companies may soon be required to self-declare whether they use mercury. This will be followed by surprise lab tests and random sampling by regulators such as the Central Drugs Standard Control Organisation (CDSCO). An official quoted by Mint said, 'The logical step is to require manufacturers to self-declare their use of mercury, propose alternative formulations, and give them a strict deadline for phasing out mercury.' How cosmetic brands are reacting Some companies have already stated their position. L'Oréal India told Mint it does not intentionally use mercury in any of its products worldwide, and that its offerings meet the highest safety standards. Other leading brands such as Lakmé, Maybelline, Sugar Cosmetics, and Nykaa did not respond to media queries. A government official noted, 'Wherever there is a casual approach in handling toxic substances, the risk to human life and the environment is high. The smarter path is to either properly manage toxic substances or stop using them entirely.' Minamata Convention also targets mercury in household items The Mint report noted that mercury-based household products—including certain medical devices—have been flagged for phase-out under the Minamata Convention. This global agreement aims to reduce human and environmental exposure to mercury. What can consumers do to protect themselves?
Mint
4 days ago
- Mint
What's that in your eye? Govt asked to ban mercury-based cosmetics
New Delhi: The Centre is deliberating a crack-down on cosmetic makers using mercury in their formulations after a government committee recommended a ban, according to officials and documents reviewed by Mint. A panel set by the Drugs Controller General of India (DCGI) has recommended that the use of mercury in cosmetic formulations be banned, documents showed. The Centre plans to identify cosmetics containing mercury and phase out their sale from the $20-billion Indian cosmetics market and from online platforms this year. Cosmetic manufacturers will have to provide self-declarations about their products being mercury-free. The products will then be put to rigorous laboratory tests for verification, officials said. A sub-committee established by the DCGI discussed banning the import, export, and manufacture of cosmetics containing over 1 part per million (ppm) of mercury, aligning with the global Minamata Convention—an international treaty designed to protect human health and the environment from the harmful effects of mercury and its compounds. Mercury content is limited under Rule 39 (5) of Cosmetics Rules, 2020. In cosmetics intended for use only in the area of eye, the level of mercury should not exceed 70 parts per million (0.007%), calculated as the metal, as a preservative. In other finished cosmetic products, 'unintentional mercury shall not exceed 1 ppm". The committee was chaired by (Prof) Dr S.N. Bhattacharya of RML Hospital's dermatology department, and included experts from pharmacology, toxicology, the Bureau of Indian Standards (BIS), the Central Drugs Standard Control Organization (CDSCO), and the environment ministry. Mercury is a toxic element that affects both human health and the environment. Products such as skin-lightening creams, 'anti-aging solutions' for freckles and dark spots and certain makeup items are known to contain mercury. 'Mercury use in the formulation of cosmetics has to be stringently discouraged/stopped," the sub-committee recommended, according to minutes of a meeting reviewed by Mint. 'Keeping mercury stocks alive for even 'safe' proportions maintains its trade, creating multiple points for potential environmental contamination during stocking, manufacturing, procuring, and transportation," said a government official familiar with the matter requesting anonymity. 'Any mishap can lead to mercury exposure in the environment which can be harmful to everyone," the official said. 'So, the logical step is to require manufacturers to self-declare their use of mercury, propose alternative formulations, and give them a strict deadline for phasing out mercury. These companies will also be required to give mandatory certification and random testing by the CDSCO by picking samples from the market," said the official. 'The matter was discussed in the Drugs Consultative Committee meeting held recently. Minimata Convention 2023 discourages the use or cosmetics in household products. In fact, mercury thermometer and BP meters were also covered in Minimata Convention. Mercury presence is hazardous for human being. Mostly eye-preparations like eye shadow etc use some mercury content as perseverative. Currently, Indian regulations allow for a certain permissible limit of mercury in some products. A sub-committee was formed to look into this matter," said a second government official who also did not want to be named. The official also noted a clear trend towards phasing out mercury in the medical devices industry. 'Today, we are seeing digital BP meters and thermometers as mercury-based devices being phased out from the medical industry," the official stated. 'Wherever there is a casual approach in the handling of toxic substances, the risk to environmental and human life is high. There is a need for either comprehensive education on proper toxic substance management or, more effectively, the discouragement of mercury use altogether," the first official said. Ruchi Mittal, R&D Head of Kaya Ltd, a chain of skin and hair clinics, emphasized the severe health consequences of mercury in cosmetics. 'Mercury can be absorbed into the bloodstream, leading to internal health issues, autoimmune conditions and potentially irreversible damage to the nervous, immune, renal and developmental systems. This grave risk is why mercury use in cosmetics is already banned in many countries," said Mittal. Queries sent to the health ministry spokesperson and DCGI remained unanswered till press time. Top cosmetic brands available in India include Lakmé, L'Oréal Paris, Maybelline, Sugar Cosmetics, and Nykaa. 'L'Oréal does not intentionally add mercury to any of its products in India or anywhere in the world. L'Oréal is highly committed to consumer safety. All the products we manufacture, distribute and market are in full compliance with regulations, subjected to rigorous evaluation and follow the highest international standards," said a L'Oréal India spokesperson. The other brands mentioned above did not respond to a request for comment till press time. Dr. Sarita Sanke, dermatologist, Apollo Spectra Hospital, Delhi said that in order to implement this initiative effectively, strategies such as the strict monitoring, awareness campaigns and transparent reporting by both manufacturers and regulators should be adopted. Digital market places should adopt robust surveillance to prevent the sale of non-compliant products. 'Mercury in cosmetics may initially give the illusion of fairer, blemish-free skin, but it comes at the cost of long-term damage, including skin thinning, rashes, discoloration, and even permanent scarring."
